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Evaluating the Management of Heart Failure in the 
Inpatient Setting 
Heart failure is one of the costliest diseases in the United States to manage and 
treat.* In 1992, an estimated 718,000 lives were affected by this disease amounting 
to greater than $6.4 billion dollars in hospital charges. With the graying of America 
and the fact that the elderly are better surviving other forms of heart disease, it is 
not surprising that the incidence of heart failure is rising. Thus, management of heart 
failure imposes a heavier financial burden to the health care system at large.  
This burden is obviously impacted by the pharmacological approach physicians take 
in managing heart disease. Mainstays of treatment have traditionally included 
reduction of volume with diuretics and strengthening of the heart's pumping function 
with digoxin. However, in recent years, major studies have shown that the emphasis 
of pharmacological management should be shifted away from the early use of 
digoxin to that of using ACE inhibitors. In these studies, ACE inhibitors were 
demonstrated to improve symptoms, decrease hospitalizations, and most 
importantly, decrease the mortality of heart failure patients. The Federal 
Government's Agency for Health Care Policy and Research (AHCPR) makes this 
recommendation in newly published guidelines regarding the diagnosis, treatment, 
and prevention of left ventricular systolic dysfunction (i.e. heart failure).  
Employing these guidelines as a template, there is a current effort to examine the 
pharmacological management of heart failure patients hospitalized at Thomas 
Jefferson University Hospital. This study is part of a larger endeavor anchored at 
Jefferson's Department of Health Policy which entails the evaluation of heart failure 
management at Thomas Jefferson in both the inpatient and outpatient areas.  
Evaluating the inpatient care of heart failure patients will involve a multi-step 
process. The first and perhaps most challenging task will be in developing the 
method by which to evaluate the therapy of patients hospitalized for heart failure. 
The AHCPR guidelines, while specific for care in the ambulatory setting, does not 
provide a "critical pathway" in treating patients admitted into the hospital for heart 
failure. Once review criteria have been formulated for treating hospitalized heart 
failure patients, a retrospective review of charts will be conducted. The charts 
reviewed will be chosen from a patient pool categorized under the heart failure DRG 
(diagnosis related group). The chart review will focus on pharmacological 
management of inpatients.  
Traditionally, physicians have been trained to treat heart failure symptomatically. 
Typically, a heart failure patient will present in the hospital with symptoms of 
shortness of breath and signs of volume overload. To relieve volume overload, the 
patient will be treated with a diuretic and later may be given digoxin in order to 
strengthen the pumping ability of the heart. Once the symptoms are alleviated and 
barring further complications, the patient is ready for discharge. Because ACE 
inhibitors do not seem to acutely relieve typical symptoms, its use may be 
overlooked, especially in the inpatient setting. The use of ACE inhibitors fits right 
along with the principle of decreasing the strain to a weaker heart by the agent's 
ability to decrease what is known as preload and afterload. In evaluating inpatient 
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heart failure treatment, we hypothesize that ACE inhibitors are underused. Aside 
from lack of awareness, the study hopes to pinpoint other potential reasons for the 
lack of ACE inhibitor use. One reason may simply be reluctance to start a new heart 
failure medication regimen in the hospital delaying any changes for outpatient care.  
In addition to reviewing the inconsistent use of ACE inhibitors in the care of 
hospitalized heart failure patients, the study aims to evaluate the use of the standard 
heart failure medications as well as inappropriate use of medications that may 
exacerbate the condition. Once the data have been collected and compiled, the 
patterns of pharmacological management of patients at Jefferson will be compared 
with the AHCPR guidelines.  
*Heart failure is a clinical syndrome or condition characterized by the degeneration 
of the heart's pumping function. The weakened heart is thus unable to supply 
enough blood to meet the demands of the body. Common signs and symptoms of 
heart failure include shortness of breath, edema, fatigue, and exercise intolerance.  
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